Our board brings together exceptional executives in science, healthcare, and business who are setting the new standard in healthcare.
For customer service, product information, new accounts or adverse events call: 877-3REV-NOW
For all other inquires call: +1 (510) 742-3400
1222 Demonbreun St
20th Floor
Nashville, TN 37203
Angus Russell has served as Chairman of the Board since March 2014. A veteran in the global biopharmaceutical industry with more than 30 years’ experience in commercial execution, operations, and strategic acquisitions, he has served on the Board of Directors of Mallinckrodt since August 2014, BioTime, Inc. since December 2014, and TherapeuticsMD, Inc. since March 2015. Mr. Russell also served as a Director at Shire Plc from 1999 to 2013. During his tenure at Shire Plc, Mr. Russell served as CEO from 2008 to 2013 and CFO from 1999 to 2008. While CEO at Shire, Mr. Russell was also the Chair of Shire’s Leadership Team and a lead member of the Shire Management Committee, which designed and implemented the company’s immensely successful long-term business strategy. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca in various senior positions, including VP of Corporate Finance at AstraZeneca.
Chris Nolet has served as a director since July 2019 and is Chair of the Audit Committee. Mr. Nolet is a retired audit partner at Ernst & Young. In addition to serving clients, his responsibilities include leading the West EY Life Sciences Industry Group and serving as a member of the Global EY Life Sciences Executive Leadership Group, which establishes policies and operating strategies for EY’s $2 billion practice worldwide. He serves on both the Executive Committee and Audit Committee (Chair) of the California Life Sciences Industry Association (CSLA) for the past 18 years and is a former member of the Finance & Investment Committee and Emerging Companies Section of BIO (the Biotechnology Innovation Organization). Additionally, Mr. Nolet serves as a Board Member and Chair of the Audit Committee at Jasper Therapeutics (NASDAQ – JSPR). Mr. Nolet is a featured speaker at the annual Davis Polk IPO conference and has testified before congress regarding the need for FDA reform. He is a CPA (California) and member of the AIPCA and the California Society of CPAs. Additionally, Mr. Nolet served on the School of Accountancy Advisory Board at his alma mater San Diego State University.
Jill Beraud has served as a director since June 2019. Ms. Beraud brings more than 25 years’ experience building luxury, fashion, beauty, and consumer brands. She was the CEO and Co‑Founder of Sh’nnong Beverage Company, a business creating a line of functional beverages. She previously served as CEO of IPPOLITA, a fine jewelry company with distribution in Bergdorf Goodman, Neiman Marcus, Nordstrom, and other national retailers. Previously she held the role of Executive Vice President, Global Retail and e‑Commerce, for Tiffany & Co., where she was responsible for all global retail, operations, e‑commerce, and omni‑channel consumer experience. Ms. Beraud has also managed brands such as Living Proof and Starbucks/Lipton Joint Ventures, and served as global chief marketing officer at PepsiCo, where she was responsible for PepsiCo’s $60 billion portfolio of food and beverage brands. She also spent 13 years at Limited Brands as chief marketing officer of Victoria’s Secret, and Executive Vice President of Marketing for its broader portfolio of specialty brands, including Bath & Body Works, Henri Bendel, and Limited Stores. Further, she has a long history of board membership with iconic brands, including Levi Strauss & Co. and Elizabeth Arden Holdings. Ms. Beraud was named to Fast Company’s “Most Creative People in Business” in 2013.
Vlad Coric has served as a director since March 2023. Dr. Coric is currently the Chairman and CEO of Biohaven, where he has successfully led the approval and commercialization of its Nurtec® ODT and CGRP franchise in addition to the expansion of company’s therapeutic portfolio targeting neurological and neuropsychiatric diseases. He also led Biohaven’s acquisition of its novel Kv7 channel platform and the sale of the Biohaven to Pfizer in October 2022 for total considerations of $13 billion. Previously, Dr. Coric was the Group Director, Neuroscience and Oncology Global Clinical Research, and Medical Director, Neuroscience Global Clinical Research, at Bristol-Myers Squibb Company. He also previously served on the board of directors of Social Capital Suvretta Holdings Corp. I (DNAA) from 2021-2022 and he currently serves on the boards of directors of private biotech companies including Veradermics, Inc., Vita Therapeutics, Inc., and Pyramid Biosciences, Inc.
During his career, Dr. Coric has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec ODT (rimegepant; oral calcitonin related peptide antagonist), zavegepant (intranasal calcitonin related peptide antagonist), Abilify® (aripiprazole; partial dopamine agonist), Opdivo® (nivolumab; anti-PD1), Yervoy® (Ipilimumab; anti-CTLA-4), Daklinza® (daclatasvir; NS5A inhibitor), and Sunvepra® (asunaprevir; NS3 inhibitor).
Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine, has published over 65 peer-reviewed publications and has lectured nationally on neurological and psychiatric disorders. He earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree.
Mark Foley is CEO of Revance Therapeutics and has served as a member of the Company’s board of directors since September 2017.
Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ). During his tenure, he led ZELTIQ’s growth from $68 million in annual revenue in 2012 to over $350 million in 2016, resulting in an appreciation of the Company’s stock of greater than tenfold and acquisition by Allergan (AGN) in April of 2017 for $2.5B. Mr. Foley also served as a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments, from 2004 to 2018.
Mr. Foley has over 25 years of experience in the health care field, having served in a variety of senior operating roles in both large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Also, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new health care companies while also serving as a Senior Advisor, Executive Chairman, interim CEO and board member to a number of medical device companies.
Mr. Foley currently serves on the board of directors of Glaukos (GKOS) and as chairman of the board for ULab. He also co-chairs the Aesthetics Innovation Summit and was chairman of Arrinex up and until its acquisition by Stryker in the spring of 2019. Mr. Foley received his BA from the University of Notre Dame in 1987 and is a named inventor on 17 patent applications.
Julian S. Gangolli has served as a director since July 2016. He was the President, North America of GW Pharmaceuticals Inc., spearheading the buildout of the company’s U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in late-stage development for a number of child-onset epilepsy syndromes. Mr. Gangolli is also a director of GW Pharmaceuticals PLC. Prior to joining GW Pharma, Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years, where he was responsible for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. Previously, he served as Senior Vice President, U.S. Eye Care at Allergan, during which time this division launched eight new products, helping to propel growth at more than 20% a year over a 5-year period. Prior to Allergan, Mr. Gangolli served in increasingly senior sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd. in the UK. Mr. Gangolli received a BSc (Honors) degree in Applied Chemistry and Business Studies from Kingston University in England.
Carey O’Connor Kolaja has served as a director since March 2021. Ms. Kolaja brings 25 years of experience as an accomplished thought leader and executive in the financial technology and payments industries. Ms. Kolaja is currently the Chief Executive Officer of AU10TIX, a global ID verification and authentication platform. Prior, Ms. Kolaja was the Global Chief Product Officer at Citi Fintech and Vice President of Global Consumer Products at PayPal. In these roles she led international teams to design, deploy, and operate global fintech and payments products. Ms. Kolaja is an author and has been featured on FOX Business, CNBC, and industry publications. She was named one of The Top 10 Women in Fintech by Fintech Magazine in 2020 and was recognized by Innotribe as one of the leading Women in Fintech bridging the gender gap. Ms. Kolaja is currently the Chairman of Everest Effect, a crisis recovery platform, and a board member for Waves for Water, an international non-profit that aims to expand the availability of clean water around the world.
Philip J. Vickers, Ph.D. has served as a director since February 2015. Dr. Vickers has spent more than 25 years in the pharmaceutical industry and is currently the President and Chief Executive Officer and a member of the board directors of Faze Medicines. Prior, he was the Chief Executive Officer and board member at Northern Biologics Inc., a developer of first-in-class immuno-oncology products. From 2011 to 2017 he served as Global Head of Research and Development at Shire, where he was responsible for overseeing preclinical research, clinical development, regulatory affairs, and medical affairs. Dr. Vickers was also a member of Shire’s Executive Committee and chaired the companies Pipeline Committee. Prior to Shire, he was Chief Scientific Officer and President at Resolvyx Pharmaceuticals, a biopharmaceutical company, from 2009 to 2011, where he was a member of the board of directors. He previously served in various capacities with international biopharmaceutical company’s including Boehringer-Ingelheim, Pfizer and Merck. Dr. Vickers was a Visiting Fellow at the National Cancer Institute in Bethesda, Maryland and holds a Ph.D. in Biochemistry from the University of Toronto, as well as a B.Sc. in Applied Biochemistry from the University of Salford, Manchester.
Olivia C. Ware has served as a director since March 2021. Ms. Ware brings more than 20 years of experience in pharmaceutical drug development, commercialization and healthcare management. She was the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., where she was responsible for developing overall portfolio strategy for the company’s three BTKi molecules. She previously served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc. Ms. Ware also worked in a number of public and private biopharma firms as a private consultant and was the Chief Commercial Officer at CytRx, Inc. Previously, Ms. Ware held various leadership roles at Genentech, Inc. and played a key role in the launch of several commercial drug products, including Rituxan®, Herceptin®, Avastin® and Lucentis®. Her expertise also includes developing managed care, pricing and contracting strategy; developing marketing programs for field-based sales teams; and establishing, growing and optimizing organizations for long-term success.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
